Stock listing

NASDAQ:SION Sionna Therapeutics, Inc. Stock

Home listing (NASDAQ) of Sionna Therapeutics, Inc.

Follow Sionna Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SION

$2.83 USD -0.15 (-4.9%)

Close on Nov 20, 2026

Past year -92.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.76 – $3.06 USDNov 20, 2026
Volume
547,657 sharesNov 20, 2026
Market cap
$127.8M USDAt the close on Nov 20, 2026 · price × 45.24M shares outstanding
52-week range
$2.76 – $54.97 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$6.12M USDMedian day 1.00M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sionna Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SION · Home$2.825 USD-0.145 (-4.9%)547,657$2.93$3.06$2.76$2.97Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SION · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.825-0.145-4.9%$2.93$3.06$2.76547,657
$2.97-0.10-3.3%$3.07$3.23$2.89515,104
$3.07-0.05-1.6%$3.13$3.17$2.99550,733
$3.12-0.21-6.3%$3.31$3.356$3.10553,297
$3.33-0.10-2.9%$3.55$3.575$3.25464,064
$3.43-0.27-7.3%$3.66$3.66$3.39411,786
$3.700.000.0%$3.74$3.855$3.68646,964
$3.70+0.13+3.6%$3.49$3.80$3.38954,688
$3.57+0.29+8.8%$3.31$3.61$3.221,089,213
$3.280.000.0%$3.27$3.355$3.19986,926
$3.28-0.45-12.1%$3.71$3.71$3.25914,859
$3.73+0.08+2.2%$3.72$3.84$3.52686,868
$3.65-0.08-2.1%$3.76$3.87$3.56902,408
$3.73-0.14-3.6%$3.91$3.935$3.65655,262
$3.87-0.13-3.2%$3.96$4.05$3.76534,344
$4.00-0.04-1.0%$4.05$4.16$3.97574,883
$4.04+0.17+4.4%$3.85$4.155$3.78952,963
$3.87+0.18+4.9%$3.68$3.905$3.631,000,646
$3.69+0.09+2.5%$3.58$3.74$3.57614,221
$3.60-0.20-5.3%$3.75$3.816$3.55917,700
$3.80-0.07-1.8%$3.87$3.97$3.6411,592,200
$3.87-0.28-6.7%$4.20$4.31$3.861,557,100
$4.15+0.14+3.5%$4.06$4.30$4.021,069,800
$4.01+0.12+3.1%$3.93$4.11$3.841,166,200
$3.89-0.19-4.7%$4.06$4.06$3.7751,484,500
$4.08-0.01-0.2%$4.15$4.30$4.02944,600
$4.09-0.29-6.6%$4.30$4.40$3.931,497,900
$4.38-0.31-6.6%$4.69$4.795$4.365790,400
$4.69-0.21-4.3%$4.89$4.93$4.675692,500
$4.900.000.0%$4.93$5.12$4.83633,600
$4.90+0.08+1.7%$4.78$4.97$4.65915,600
$4.82+0.07+1.5%$4.68$4.87$4.61880,100
$4.75-0.10-2.1%$4.88$4.88$4.521,259,900
$4.85-0.06-1.2%$4.95$4.96$4.631,097,000
$4.91-0.19-3.7%$5.19$5.19$4.861,159,300
$5.10-0.16-3.0%$5.26$5.33$5.031,056,700
$5.26+0.11+2.1%$5.19$5.342$5.021,157,500
$5.15+0.03+0.6%$5.15$5.19$5.025797,500
$5.12-0.11-2.1%$5.17$5.25$5.05775,600
$5.230.000.0%$5.28$5.30$5.091,401,500
$5.23-0.28-5.1%$5.50$5.59$5.1521,246,700
$5.51-0.51-8.5%$6.03$6.12$5.321,668,800
$6.02+0.02+0.3%$5.99$6.17$5.841,693,900
$6.00+0.04+0.7%$6.00$6.13$5.702,522,700
$5.96-1.22-17.0%$7.12$7.19$5.903,704,800
$7.18+0.14+2.0%$7.27$7.73$7.151,476,800
$7.04+0.16+2.3%$6.95$7.368$6.911,970,800
$6.88-1.38-16.7%$7.87$8.00$6.852,461,800
$8.26+0.41+5.2%$7.84$8.535$7.841,210,600
$7.85+0.23+3.0%$7.79$8.03$7.471,208,100
$7.62+0.14+1.9%$7.40$7.75$7.121,222,600
$7.48+0.18+2.5%$7.27$7.55$7.169766,100
$7.30+0.12+1.7%$7.13$7.555$6.89884,700
$7.18+0.43+6.4%$6.68$7.22$6.62921,800
$6.75-0.56-7.7%$7.31$7.56$6.701,242,200
$7.31+0.85+13.2%$6.63$7.35$6.271,590,500
$6.46+0.43+7.1%$5.95$6.48$5.931,404,800
$6.03+0.16+2.7%$5.87$6.08$5.751,382,300
$5.87-0.19-3.1%$5.97$6.06$5.822783,100
$6.06-0.11-1.8%$6.14$6.25$5.97773,900
$6.17-0.08-1.3%$6.20$6.29$6.02923,800
$6.25+0.66+11.8%$5.60$6.30$5.581,973,200
$5.59+0.30+5.7%$5.29$5.61$5.211,773,800
$5.29-0.23-4.2%$5.54$5.72$5.271,937,800
$5.52-0.73-11.7%$6.27$6.273$5.511,749,500
Ticker
NASDAQ:SION
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Sionna Therapeutics, Inc. news

Sionna Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 34 in all · newest Nov 10, 2026 · oldest 2025
Decks
11 decks · latest Sep 14, 2026

Where Sionna Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SION · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SIONBOATSUnited StatesUSD

Valuation

Price/book 0.5× against a median of 5.0×: the lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$89.05M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.51

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sionna Therapeutics, Inc. · NASDAQ:SIONUS$127.8M−US$89.05Mn/an/an/a0.5×n/a0.0×1.51
Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTLUS$133.6M−US$62.81Mn/an/an/a0.7×n/a0.2×1.44
Starpharma Holdings Limited · ASX:SPLUS$133.4MUS$126.5Mn/a15.9×n/a14.6×−62.0%0.1×n/a
Yoda Pharmaceuticals Inc. · TPEX:7829US$127.1MUS$94.39Mn/an/an/a3.9×n/a0.0×n/a
IntoCell, Inc. · KRX:287840US$126.5MUS$108.8Mn/a45.9×n/a8.7×−295.9%0.0×n/a
UnicoCell Biomed Co., Ltd. · TWSE:6794US$126.3MUS$106.5Mn/a117×n/a5.1×−381.5%0.1×n/a
MacroGenics, Inc. · NASDAQ:MGNXUS$125.3M−US$127.6Mn/a−0.9×n/a5.0×−34.6%1.4×0.83
PolyPid Ltd. · NASDAQ:PYPDUS$124.3MUS$119.3Mn/an/an/a23.1×n/a0.3×0.93
Compass Therapeutics, Inc. · NASDAQ:CMPXUS$123.9M−US$29.89Mn/an/an/a0.9×n/a0.1×1.22
Humacyte, Inc. · NASDAQ:HUMAUS$123.7MUS$96.01Mn/a40.1×n/a6.8×n/a2.0×2.56
Biomm SA · BMFBOVESPA:BIOM3US$122.6MUS$136.5M18.4×2.1×12.3×2.2×10.3%0.3×n/a
Median of the othersUS$125.8MUS$101.3M18.4×28.0×12.3×5.0×−62.0%0.1×1.22

Forecasts

2 strong buy · 10 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
21.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.62 · 5 analysts

Team and board

Officers

OfficerRole
Ashley ParksVice President, Chief of Staff to CEO and Program Lead
Mike CloonanPresident and Chief Executive Officer
Elena RidloffChief Financial Officer & Chief Business Officer
Erica IorioVice President, Finance and Controller
Jen FitzpatrickChief Legal Officer & Head of Program Management
Alison EasterVice President, Preclinical Safety
Cécile Le CamusVice President, Medical Affairs, Patient Advocacy, & Development Operations
Mara FurlowSenior Vice President, Global Regulatory Affairs and Quality
Mark TroneSenior Vice President, Head of Technical Operations
Roxanne McGrathVice President, Head of Human Resources
Charlotte McKeeHead of R&D & Chief Medical Officer

Board

DirectorRole
Paul ClancyChair
Bruce BoothDirector
Edd FlemingDirector
Jo VineyDirector
Josh ResnickDirector
Laurie StelzerDirector
Lucian IancoviciDirector
Marcella Kuhlman RuddyDirector
Mike CloonanPresident and Chief Executive Officer
Peter ThompsonDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open+3.6%
Q2 2026Aug 6, 2026 · Before open+4.8%
Q1 2026May 12, 2026 · Before open−10.9%
Q4 2025Mar 19, 2026+5.8%
Q3 2025Nov 5, 2025 · Before open−1.6%
Q2 2025Aug 11, 2025 · Before open+13.4%
Q1 2025May 12, 2025 · Before open+4.7%
Q4 2024Mar 20, 2025−1.4%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (September 2026)Corporate update23 slidesSep 14, 2026
Corporate Update (August 2026)Corporate update14 slidesAug 10, 2026
49th European Cystic Fibrosis Conference 2026Conference11 slidesJune 2026
NACFC (North American Cystic Fibrosis Conference) 2025Conference16 slidesMar 2, 2026
Technical Presentation (2025)Technical10 slidesJun 6, 2025
Investor Presentation (August 2024)Investor deck20 slidesAugust 2024
Investor Presentation (July 2024)Investor deck20 slidesJul 16, 2024
42nd Annual J.P. Morgan Healthcare Conference 2024Conference14 slidesJanuary 2024
41st Annual J.P. Morgan Healthcare Conference (January 2023)Conference17 slidesJanuary 2023
North American Cystic Fibrosis Conference 2022Conference15 slidesDec 23, 2022
All 11 decks
DeckKindSlidesDate
Stifel Healthcare Conference 2022Conference16 slidesNov 15, 2022

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$219.2M raised · US$18 a share · Goldman Sachs & Co. LLC +3
Dealers: Goldman Sachs & Co. LLC (co-lead), TD Cowen (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead)
Feb 10, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Feb 6, 2025.

Price
US$18.00 a share
Shares offered
10,588,233 shares of common stock
Offering size
US$190.6 million
Underwriters' option
Up to 1,588,234 more shares
Underwriters
Goldman Sachs & Co. LLC, TD Cowen, Stifel, Guggenheim Securities · In the order on the cover
Shares delivered
On or about Feb 10, 2025

Steps

StepWhen
Draft sent to the SEC in confidenceSep 12, 2024
Filed publiclyJan 17, 2025
Amended onceFeb 3, 2025
Shares registered with an exchangeFeb 4, 2025
Declared effective by the SECFeb 6, 2025
Final prospectus, with the priceFeb 7, 2025

Open IPO · From the cover of the final prospectus (424B4) filed Feb 7, 2025

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Cost of revenue647.0K668.0K
Gross profit-647.0K-668.0K
Research and development60.3M57.3M40.6M34.6M
Selling, general and administrative28.7M13.3M9.71M6.77M
Operating income-89.0M-70.6M-50.3M-41.4M
Depreciation and amortization647.0K668.0K583.0K122.0K
EBITDA-88.3M-69.9M-49.8M-41.3M
Income before tax-75.3M-61.7M-47.3M-40.2M
Income tax00
Net income-75.3M-61.7M-47.3M-40.2M
Earnings per share, basic-1.88-15.99-1.07-0.91
Earnings per share, diluted-1.88-15.99

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents58.5M37.8M38.5M54.8M
Short-term investments177.4M109.8M027.8M
Current assets241.4M151.0M39.2M83.8M
Property, plant and equipment2.23M2.47M
Total assets326.0M185.8M51.9M87.4M
Accounts payable769.0K1.19M719.0K557.0K
Current liabilities11.7M10.4M8.04M8.25M
Total debt8.68M9.75M10.5M
Total liabilities19.1M19.1M166.8M157.3M
Shareholders' equity306.8M-163.7M-114.9M-69.9M
Shares outstanding44.7M4.72M44.1M44.1M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-66.3M-52.8M-43.7M-36.1M
Capital spending-377.0K-27.0K-1.12M-1.87M
Free cash flow-66.7M-52.8M-44.8M-37.9M
Cash from investing-118.7M-126.9M27.4M-29.3M
Cash from financing205.7M179.0M31.0K110.9M
Change in cash20.7M-733.0K-16.3M45.5M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 9, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 21, 2026Big-stake noticeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 14, 2026Management or board changeSEC
8-K · Current reportAug 10, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
144/A · Notice of proposed sale, amendedJun 1, 2026Other filingsSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
144 · Notice of proposed saleMay 29, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 27, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 20, 2026Big-stake noticeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 2, 2026Offer documentSEC
S-3ASR · Registration statementMar 2, 2026Offer documentSEC
10-K · Annual reportMar 2, 2026Annual reportSEC
8-K · Current reportMar 2, 2026ResultsSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
144 · Notice of proposed saleNov 21, 2025Other filingsSEC
144 · Notice of proposed saleNov 21, 2025Other filingsSEC
144 · Notice of proposed saleNov 21, 2025Other filingsSEC
144 · Notice of proposed saleNov 21, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 31, 2025Big-stake noticeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
144 · Notice of proposed saleOct 28, 2025Other filingsSEC
144 · Notice of proposed saleOct 28, 2025Other filingsSEC
144 · Notice of proposed saleOct 28, 2025Other filingsSEC
144 · Notice of proposed saleOct 28, 2025Other filingsSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
144 · Notice of proposed saleOct 24, 2025Other filingsSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
144 · Notice of proposed saleOct 21, 2025Other filingsSEC
144 · Notice of proposed saleOct 21, 2025Other filingsSEC
144 · Notice of proposed saleOct 21, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 20, 2025Big-stake noticeSEC
4 · Change in ownershipOct 20, 2025Insider tradeSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
144 · Notice of proposed saleOct 14, 2025Other filingsSEC
144 · Notice of proposed saleOct 14, 2025Other filingsSEC
144 · Notice of proposed saleOct 10, 2025Other filingsSEC
144 · Notice of proposed saleOct 10, 2025Other filingsSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
144 · Notice of proposed saleOct 6, 2025Other filingsSEC
144 · Notice of proposed saleOct 6, 2025Other filingsSEC
144 · Notice of proposed saleOct 3, 2025Other filingsSEC
144 · Notice of proposed saleOct 3, 2025Other filingsSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
144 · Notice of proposed saleSep 30, 2025Other filingsSEC
144 · Notice of proposed saleSep 30, 2025Other filingsSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
144 · Notice of proposed saleSep 29, 2025Other filingsSEC
144 · Notice of proposed saleSep 29, 2025Other filingsSEC
144 · Notice of proposed saleSep 26, 2025Other filingsSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
144 · Notice of proposed saleSep 4, 2025Other filingsSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
144 · Notice of proposed saleAug 26, 2025Other filingsSEC
144 · Notice of proposed saleAug 26, 2025Other filingsSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC
144 · Notice of proposed saleAug 20, 2025Other filingsSEC
144 · Notice of proposed saleAug 20, 2025Other filingsSEC
144 · Notice of proposed saleAug 19, 2025Other filingsSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2025Big-stake noticeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 16, 2025Big-stake noticeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
8-K · Current reportJun 4, 2025Current reportSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
3 · Initial statement of ownershipApr 1, 2025Insider tradeSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
SCHEDULE 13D · Big-stake noticeFeb 18, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 18, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 18, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 18, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 13, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
8-K · Current reportFeb 10, 2025Current reportSEC
S-8 · Registration statement for employee plansFeb 7, 2025Offer documentSEC

This page holds 200 of 234 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Sionna Therapeutics, Inc.’s releases · as of Oct 30, 2026

Common shares
45,235,568
Fully diluted
45,235,568

Fully diluted

LineSharesAs of
Common shares45,235,568Oct 30, 2026

Share count over time

CountShares
Oct 30, 202645,235,568

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Tpg Gp A, LLC6.49MUS$34.2MSep 30, 2026
Ra Capital Management, L.P.6.46MUS$34MSep 30, 2026
Viking Global Investors LP3.2MUS$16.8MSep 30, 2026
Atlas Venture Life Science Advisors, LLC3MUS$15.8MSep 30, 2026
Goldman Sachs2.72MUS$14.3MSep 30, 2026
BlackRock2.68MUS$14.1MSep 30, 2026
Enavate Sciences Gp, LLC2.48MUS$13MSep 30, 2026
Orbimed Advisors LLC2.47MUS$13MSep 30, 2026
Jennison Associates LLC1.99MUS$10.5MSep 30, 2026
Vanguard1.66MUS$8.71MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Millennium1.46MUS$7.69MSep 30, 2026
abrdn1.34MUS$7.06MSep 30, 2026
Y-Intercept (Hong Kong) Ltd1.06MUS$5.56MSep 30, 2026
Acadian Asset Management LLC554KUS$2.91MSep 30, 2026
Geode Capital540KUS$2.84MSep 30, 2026
Walleye Capital LLC453KUS$2.38MSep 30, 2026
Marshall Wace, LLP444KUS$2.34MSep 30, 2026
Voleon Capital Management LP430KUS$2.26MSep 30, 2026
Boxer Capital Management, LLC392KUS$2.06MSep 30, 2026
Bank of America378KUS$1.99MSep 30, 2026
State Street377KUS$1.98MSep 30, 2026
BNP Paribas335KUS$1.76MSep 30, 2026
AQR Capital Management LLC326KUS$1.72MSep 30, 2026
Morgan Stanley304KUS$1.6MSep 30, 2026
Point72 Asset Management, L.P.263KUS$1.39MSep 30, 2026
HSBC261KUS$1.34MSep 30, 2026
Trexquant Investment LP234KUS$1.23MSep 30, 2026
Susquehanna213KUS$1.12MSep 30, 2026
Schonfeld Strategic Advisors LLC171KUS$898KSep 30, 2026
Northern Trust169KUS$888KSep 30, 2026
Jump Financial, LLC161KUS$849KSep 30, 2026
Schwab146KUS$768KSep 30, 2026
Citigroup Inc134KUS$705KSep 30, 2026
Tang Capital Management LLC125KUS$658KSep 30, 2026
Quantinno Capital Management LP113KUS$595KSep 30, 2026
Jane Street105KUS$554KSep 30, 2026
Rock Springs Capital Management LP99,429US$523KSep 30, 2026
UBS94,449US$497KSep 30, 2026
Algert Global LLC91,770US$483KSep 30, 2026
Gsa Capital Partners LLP88,680US$466KSep 30, 2026
Caitong International Asset Management Co., Ltd88,580US$466KSep 30, 2026
Rhenman & Partners Asset Management AB87,500US$460KSep 30, 2026
Driehaus Capital Management LLC87,272US$459KSep 30, 2026
Ikarian Capital, LLC85,300US$449KSep 30, 2026
Axq Capital, LP71,794US$378KSep 30, 2026
Jain Global LLC70,918US$373KSep 30, 2026
Opaleye Management Inc.70,000US$368KSep 30, 2026
ExodusPoint Capital Management, LP65,520US$345KSep 30, 2026
Alps Advisors Inc59,475US$313KSep 30, 2026
Nuveen53,199US$280KSep 30, 2026

This page holds 50 of 129 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund935KUS$41.1MJun 30, 2026
PGIM Jennison Health Sciences Fund651KUS$27.9MMay 29, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF648KUS$28.5MJun 30, 2026
JPMorgan Small Cap Growth Fund524KUS$23.1MJun 30, 2026
iShares Russell 2000 ETF484KUS$21.3MJun 30, 2026
Eventide Healthcare & Life Sciences Fund475KUS$20.9MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.288KUS$12.7MJun 30, 2026
Fidelity Small Cap Index Fund202KUS$9.51MJul 31, 2026
iShares Biotechnology ETF186KUS$8.17MJun 30, 2026
iShares Russell 2000 Growth ETF173KUS$7.62MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Vanguard Extended Market Index Fund168KUS$7.41MJun 30, 2026
JPMorgan Small Cap Blend Fund167KUS$7.33MJun 30, 2026
Artisan International Small-Mid Fund116KUS$5.12MJun 30, 2026
Franklin Biotechnology Discovery Fund108KUS$5.09MJul 31, 2026
Vanguard Russell 2000 Index Fund83,317US$3.57MMay 31, 2026
Multi-Manager Small Cap Equity Strategies Fund83,093US$3.56MMay 31, 2026
Select Biotechnology Portfolio80,900US$3.46MMay 31, 2026
Fidelity Extended Market Index Fund73,777US$3.16MMay 31, 2026
T. Rowe Price New Horizons Fund, Inc.70,768US$3.11MJun 30, 2026
Schwab U.S. Small-Cap ETF69,810US$2.99MMay 31, 2026
Vanguard U.S. Momentum Factor ETF55,058US$2.36MMay 31, 2026
Driehaus Micro Cap Growth Fund46,945US$2.07MJun 30, 2026
ALPS Medical Breakthroughs ETF46,379US$1.99MMay 31, 2026
Schwab Small-Cap Index Fund44,674US$2.11MJul 31, 2026
Master Small Cap Index Series34,469US$1.52MJun 30, 2026
Fidelity Nasdaq Composite Index Fund27,764US$1.19MMay 31, 2026
Fidelity Total Market Index Fund26,184US$1.12MMay 31, 2026
Nuveen Small Cap Blend Index Fund24,424US$1.15MJul 31, 2026
Adara Smaller Companies Fund22,844US$978KMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares22,009US$1.04MJul 31, 2026
Fidelity Series Total Market Index Fund21,764US$932KMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF21,536US$947KJun 30, 2026
EQ/2000 Managed Volatility Portfolio20,147US$886KJun 30, 2026
T. Rowe Price Health Sciences Portfolio17,807US$783KJun 30, 2026
EQ/Small Company Index Portfolio17,790US$783KJun 30, 2026
Fidelity Small Cap Growth Index Fund17,278US$760KJun 30, 2026
Vanguard Russell 2000 Growth Index Fund15,150US$649KMay 31, 2026
Vanguard Balanced Index Fund14,944US$657KJun 30, 2026
LVIP Franklin Templeton Multi-Factor SMID Cap Equity Fund14,508US$638KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund14,099US$620KJun 30, 2026
Fidelity Nasdaq Composite Index ETF13,843US$593KMay 31, 2026
LVIP State Street Small-Cap Index Fund13,200US$581KJun 30, 2026
Nuveen Equity Index Fund12,533US$591KJul 31, 2026
Small Cap Index Fund9,298US$409KJun 30, 2026
Global X Russell 2000 ETF8,820US$416KJul 31, 2026
Schwab Total Stock Market Index Fund8,762US$413KJul 31, 2026
Virtus Biotech Clinical Trials Etf8,653US$408KJul 31, 2026
U.S. Small Cap Equity Fund8,456US$399KJul 31, 2026
Destinations Small-Mid Cap Equity Fund8,167US$350KMay 31, 2026
Fidelity ZERO Total Market Index Fund7,675US$362KJul 31, 2026

This page holds 50 of 136 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Ra Capital Management, L.P.
Director, 10% owner
Sale3,415,011USD 6.32US$21.6MSep 17, 2026
Ra Capital Management, L.P.
Director, 10% owner
Sale33,800USD 7.46US$252KSep 17, 2026
OrbiMed Capital GP VIII LLC
Director
Sale85,918USD 44.86US$3.85MJul 7, 2026
Thompson Peter A.
Director
Sale85,918USD 44.86US$3.85MJul 7, 2026
Fitzpatrick Jennifer
Officer: Chief Legal Officer
Sale10,250USD 43.60US$447KJul 6, 2026
Orbimed Advisors LLC
Director
Sale115,844USD 45.50US$5.27MJun 30, 2026
Thompson Peter A.
Director
Sale115,844USD 45.50US$5.27MJun 30, 2026
Orbimed Advisors LLC
Director
Sale101USD 44.49US$4,493May 27, 2026
Thompson Peter A.
Director
Sale101USD 44.49US$4,493May 27, 2026
Orbimed Advisors LLC
Director
Sale184,639USD 46.22US$8.53MMay 11, 2026
All 25 trades
TradeTradeSharesPriceValueDate
Thompson Peter A.
Director
Sale184,639USD 46.22US$8.53MMay 11, 2026
Orbimed Advisors LLC
Director
Sale59,767USD 44.58US$2.66MMay 8, 2026
Thompson Peter A.
Director
Sale59,767USD 44.58US$2.66MMay 8, 2026
Orbimed Advisors LLC
Director
Sale48,546USD 44.61US$2.17MMay 7, 2026
Thompson Peter A.
Director
Sale48,546USD 44.61US$2.17MMay 7, 2026
Orbimed Advisors LLC
Director
Sale2,948USD 44.52US$131KApr 18, 2026
Thompson Peter A.
Director
Sale2,948USD 44.52US$131KApr 18, 2026
Orbimed Advisors LLC
Director
Sale52,397USD 44.68US$2.34MApr 17, 2026
Thompson Peter A.
Director
Sale52,397USD 44.68US$2.34MApr 17, 2026
Orbimed Advisors LLC
Director
Sale226,906USD 45.34US$10.3MApr 16, 2026
Thompson Peter A.
Director
Sale226,906USD 45.34US$10.3MApr 16, 2026
Orbimed Advisors LLC
Director
Sale235,863USD 44.64US$10.5MApr 15, 2026
Thompson Peter A.
Director
Sale235,863USD 44.64US$10.5MApr 15, 2026
Orbimed Advisors LLC
Director
Sale47,814USD 44.51US$2.13MApr 14, 2026
Thompson Peter A.
Director
Sale47,814USD 44.51US$2.13MApr 14, 2026

Big stakes

StakeStakeSharesDateFiling
Tpg Gp A, LLC15.20%6.68MFeb 10, 2025Schedule 13D
Ra Capital Management, L.P.14.30%6.48MSep 17, 2026Schedule 13D
Viking Global Investors LP7.10%3.2MMar 31, 2026Schedule 13G
Orbimed Advisors LLC6.60%2.97MApr 15, 2026Schedule 13D
Goldman Sachs Group Inc5.80%2.64MSep 30, 2026Schedule 13G
Enavate Sciences Gp, LLC5.60%2.48MFeb 10, 2025Schedule 13D
Atlas Venture Fund XI, L.P.5.40%2.38MOct 16, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Feb 6, 2025
Bruce Booth
Other companies: Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Tectonic Therapeutic, Inc. (Director · Jun 10, 2021 – Jun 6, 2023 · Past); Dianthus Therapeutics, Inc. (Director · Jun 1, 2021 – Jun 28, 2022 · Past)
Director · Since at least Feb 6, 2025
Elena Ridloff
Other companies: Immunic, Inc. (Director · Since at least Aug 6, 2026); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020); ACADIA Pharmaceuticals Inc. (EVP and CFO · Jan 6, 2021 – Apr 29, 2021 · Past)
CFO and CBO · Since at least Feb 6, 2025
Joshua Resnick
Other companies: Cidara Therapeutics Inc (Director · Since at least Jan 3, 2025); PepGen Inc. (Director · Since at least Jun 20, 2024); Jade Biosciences, Inc. (Director · Jun 5, 2024 – Jun 5, 2024 · Past); Vor Biopharma Inc. (Director · May 23, 2024 – May 22, 2025 · Past)
Director · Since at least Feb 6, 2025
Laurie Stelzer
Other companies: MBX Biosciences, Inc. (Director · Since at least Jan 20, 2026); Spyre Therapeutics, Inc. (Chair of the Audit Committee · Since at least Nov 22, 2023); PMV Pharmaceuticals, Inc. (Chair, Board of Directors · Since at least Jun 2, 2022); Surface Oncology Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past)
Director · Since at least Feb 6, 2025
Joanne L Viney
Other companies: LENZ Therapeutics, Inc. (Director · Jun 24, 2021 – Jul 19, 2023 · Past); Pandion Therapeutics Inc (See Remarks · Jul 16, 2020 – Apr 1, 2021 · Past); Harpoon Therapeutics Inc (Director · Jul 1, 2020 – Apr 1, 2023 · Past)
Director · Since at least Feb 6, 2025
Lucian Iancovici
Other companies: Achieve Life Sciences, Inc. (Chairman of the Board of Directors · Since at least Apr 17, 2026); Rallybio Corporation (Board Member · Since at least Jul 29, 2021); CeriBell, Inc. (Director · Oct 10, 2024 – Oct 10, 2024 · Past)
Director · Since at least Feb 6, 2025
Harold Edward Fleming
Other companies: Upstream Bio, Inc. (Director · Since at least Oct 10, 2024); CRISPR Therapeutics AG (Director · Since at least Jun 10, 2021)
Director · Since at least Feb 6, 2025
Marcella Kuhlman Ruddy
Other companies: Upstream Bio, Inc. (Chief Medical Officer, Tectonic Therapeutic · Since at least Oct 10, 2024); Tectonic Therapeutic, Inc. (Chief Medical Officer · Since at least Jun 20, 2024)
Director · Since at least Feb 6, 2025
Michael Cloonan
Other companies: Bluebird bio Inc (Director · Since at least Jun 20, 2024); Sage Therapeutics Inc (Chief Business Officer · Apr 2, 2018 – Feb 10, 2021 · Past)
President & CEO, Director · Since at least Feb 6, 2025
All 27 people
PersonSeat
Peter Thompson
Other companies: ARS Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026); Aspen Neuroscience, Inc. (Director · Since at least Nov 2, 2026)
Director · Since at least Apr 14, 2026
Edd Fleming
Other companies: Upstream Bio, Inc. (Executive Vice President, Enavate Sciences · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
Josh Resnick
Other companies: PepGen Inc. (Non-Executive Director · Since at least Nov 4, 2026)
Director · Since at least Nov 4, 2026
Alison EasterVice President, Preclinical Safety · Since at least Nov 4, 2026
Ashley ParksVice President, Chief of Staff to CEO and Program Lead · Since at least Nov 4, 2026
Caroline Stark BeerChief Business Officer · Since at least Sep 8, 2025
Cécile Le CamusVice President, Medical Affairs, Patient Advocacy, & Development Operations · Since at least Nov 4, 2026
Charlotte McKeeHead of R&D & Chief Medical Officer · Since at least Feb 6, 2025
Erica IorioVice President, Finance and Controller · Since at least Nov 4, 2026
Jen FitzpatrickChief Legal Officer & Head of Program Management · Since at least Sep 18, 2026
Jennifer FitzpatrickCLO and Head of Program Mgmt. · Since at least Jul 6, 2026
Jo VineyDirector · Since at least Mar 20, 2025
Mara FurlowSenior Vice President, Global Regulatory Affairs and Quality · Since at least Nov 4, 2026
Mark TroneSenior Vice President, Head of Technical Operations · Since at least Nov 4, 2026
Mike CloonanPresident and Chief Executive Officer · Since at least Sep 14, 2026
Paul ClancyChair · Since at least Nov 5, 2026
Roxanne McGrathVice President, Head of Human Resources · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Sionna Therapeutics, Inc.